Donepezil Hydrochloride Tablet, Film Coated
Product Images NDC 42799-954

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 42799-954). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Edenbridge Pharmaceuticals Llc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

1 (Donepezil 23mg 30count)

1 (Donepezil 23mg 30count)
Label for Donepezil Hydrochloride Tablets 23 mg in a 30-count package by Edenbridge Pharmaceuticals LLC. The label includes storage instructions, a barcode, and states that each tablet contains 23 mg of donepezil hydrochloride. The product is prescription only and advises referring to prescribing information for dosage and use.*
FDA Label Image

1 (Donepezil 23mg 90count)

1 (Donepezil 23mg 90count)
Donepezil Hydrochloride 23 mg film-coated tablets label showing a package of 90 tablets. The label includes storage instructions, manufacturer Dexcel Pharma Technologies Ltd. (Israel), and distributor Edenbridge Pharmaceuticals LLC (Parsippany, NJ). It features barcoding and dosage confirmation, marked Rx Only.*
FDA Label Image

1 (Donepezil Hydrochloride)

1 (Donepezil Hydrochloride)
Chemical structure of Donepezil hydrochloride depicted as a molecular diagram showing its atomic and bond arrangement.*
FDA Label Image

1 (Figure 1)

1 (Figure 1)
A line graph showing the ADAS-cog mean change from baseline with standard error over 30 weeks of drug treatment. It compares Donepezil Hydrochloride 10 mg/day, Donepezil Hydrochloride 5 mg/day, and placebo groups. The graph indicates clinical improvement versus clinical decline over time for the three groups.*
FDA Label Image

1 (Figure 10)

1 (Figure 10)
A cumulative percentage plot showing the distribution of ADCS-ADL change from baseline in patients treated with Donepezil Hydrochloride 10 mg/day versus placebo. The x-axis represents the ADCS-ADL change from baseline, ranging from positive to negative values, while the y-axis indicates the cumulative percentage of patients, ranging from 0 to 100 percent. Two curves compare the effects of donepezil and placebo on functional change.*
FDA Label Image

1 (Figure 11)

1 (Figure 11)
A line graph depicting SIB (Severe Impairment Battery) change from baseline over 24 weeks of drug treatment. Two lines represent Donepezil Hydrochloride dosages: 23 mg/day and 10 mg/day. The graph shows separate trends for clinical improvement and decline across the study period.*
FDA Label Image

1 (Figure 12)

1 (Figure 12)
A line graph comparing the cumulative percentage of patients experiencing SIB change from baseline for Donepezil hydrochloride 23 mg/day and 10 mg/day doses. The y-axis shows the cumulative percentage of patients, and the x-axis shows the SIB change from baseline, illustrating patient response distributions for both dosages.*
FDA Label Image

1 (Figure 13)

1 (Figure 13)
Bar chart comparing CIBIC-plus Rating results between Donepezil Hydrochloride 23 mg/day and 10 mg/day. The vertical axis shows the percentage of patients, and the horizontal axis lists CIBIC-plus categories: Markedly Improved, Moderately Improved, Minimally Improved, No Change, Minimally Worse, Moderately Worse, Markedly Worse. Black bars represent 23 mg/day, white bars represent 10 mg/day dose groups.*
FDA Label Image

1 (Figure 2)

1 (Figure 2)
A cumulative percentage curve graph showing the change from baseline on the ADAS-cog cognitive assessment for patients taking Donepezil Hydrochloride tablets at 5 mg/day and 10 mg/day dosages compared to placebo. The graph illustrates the proportion of patients achieving various improvements, with separate curves for each group and marked points indicating changes of 7 and 4 points. A small inset table summarizes the percentage of patients with changes of -7, -4, and 2 or more points.*
FDA Label Image

1 (Figure 3)

1 (Figure 3)
A bar graph showing CIBIC-plus Rating of patients categorized by treatment groups: Donepezil Hydrochloride 10 mg/day, Donepezil Hydrochloride 5 mg/day, and Placebo. The x-axis shows categories from 'Markedly Improved' to 'Markedly Worse,' and the y-axis represents the percentage of patients in each category.*
FDA Label Image

1 (Figure 4)

1 (Figure 4)
A line graph showing ADAS-cog change from baseline (mean ± SE) over 15 weeks of drug treatment, comparing Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo. The y-axis ranges from clinical improvement (-4) to clinical decline (+2), with data points indicating changes at various weeks. Donepezil doses show improvement, while placebo trends toward decline.*
FDA Label Image

1 (Figure 5)

1 (Figure 5)
A cumulative percentage graph showing change from baseline in ADAS-cog scores for Donepezil Hydrochloride tablets at 5 mg/day and 10 mg/day compared to placebo over time. The chart includes a legend and a small table summarizing percentage improvement at various time points for each treatment group.*
FDA Label Image

1 (Figure 6)

1 (Figure 6)
A bar chart depicting the CIBIC-plus Rating distribution of patients across different categories including Markedly Improved, Moderately Improved, Minimally Improved, No Change, Minimally Worse, Moderately Worse, and Markedly Worse. The graph compares three groups: Donepezil Hydrochloride 10 mg/day, Donepezil Hydrochloride 5 mg/day, and Placebo, showing the percentage of patients in each category.*
FDA Label Image

1 (Figure 7)

1 (Figure 7)
Graph showing the SIB (Severe Impairment Battery) change from baseline over 6 months of drug treatment comparing Donepezil Hydrochloride 10 mg/day with a placebo. The y-axis represents mean change from baseline, indicating clinical improvement or decline, while the x-axis represents time in months. Donepezil shows clinical improvement, whereas placebo shows decline.*
FDA Label Image

1 (Figure 8)

1 (Figure 8)
A cumulative percentage of patients chart comparing Donepezil Hydrochloride 10 mg/day versus placebo. The X-axis represents SIB change from baseline, and the Y-axis shows the cumulative percentage of patients, illustrating the distribution of responses between the two groups.*
FDA Label Image

1 (Figure 9)

1 (Figure 9)
A line graph depicting the mean change from baseline in ADCS-ADL scores with standard error bars over 6 months of drug treatment. It compares Donepezil hydrochloride 10 mg/day versus placebo, showing trends of clinical improvement or decline over time.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.